NEW YORK (AP) -- Pfizer Inc. said Wednesday it completed the buyout of FoldRx Pharmaceuticals Inc., a privately held drug discovery and clinical development company.
On Sept. 1, Pfizer said it would buy FoldRx for an undisclosed amount in a move to expand its pipeline of products.
FoldRx, based in Cambridge, Massachusetts, is developing potential treatments for diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases. The lead product candidate is tafamidis meglumine, aimed at treating TTR amyloid polyneuropathy, a progressively fatal genetic neurodegenerative disease.
Liver transplants are currently the only treatment option.
On Sept. 1, Pfizer said it would buy FoldRx for an undisclosed amount in a move to expand its pipeline of products.
FoldRx, based in Cambridge, Massachusetts, is developing potential treatments for diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases. The lead product candidate is tafamidis meglumine, aimed at treating TTR amyloid polyneuropathy, a progressively fatal genetic neurodegenerative disease.
Liver transplants are currently the only treatment option.
